Refine your search
-
Authors
-
Item types
-
Topics
- *Atherosclerosis
- *Cost-Benefit Analysis
- *Eicosapentaenoic Acid/ec [Economics]
- *Eicosapentaenoic Acid/tu [Therapeutic Use]
- *Hydroxymethylglutaryl-CoA Reductase Inhibitors
- *Hydroxymethylglutaryl-CoA Reductase Inhibitors/ec [Economics]
- *Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use] [x]
- *Hyperlipidemias
- *Hyperlipidemias/dt [Drug Therapy]
- *Hyperlipidemias/ec [Economics]
- Aged
- Atherosclerosis/dt [Drug Therapy]
- Cholesterol, LDL
- Dicarboxylic Acids
- Eicosapentaenoic Acid/aa [Analogs & Derivatives]
- Ezetimibe/tu [Therapeutic Use]
- Fatty Acids
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
- Show more
- Show less
-
Collections
-
Languages